



**HAL**  
open science

## **Variants in Solute Carrier SLC26A9 Modify Prenatal Exocrine Pancreatic Damage in Cystic Fibrosis**

Melissa Miller, David Soave, Weili Li, Jiafen Gong, Rhonda Pace, Pierre-Yves Boëlle, Garry Cutting, Mitchell Drumm, Michael Knowles, Lei Sun, et al.

► **To cite this version:**

Melissa Miller, David Soave, Weili Li, Jiafen Gong, Rhonda Pace, et al.. Variants in Solute Carrier SLC26A9 Modify Prenatal Exocrine Pancreatic Damage in Cystic Fibrosis. *The Journal of Pediatrics*, 2015, 166 (5), pp.1152-1157.e6. 10.1016/j.jpeds.2015.01.044 . hal-03829122

**HAL Id: hal-03829122**

**<https://hal.science/hal-03829122v1>**

Submitted on 15 Jul 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Published in final edited form as:

*J Pediatr.* 2015 May ; 166(5): 1152–1157.e6. doi:10.1016/j.jpeds.2015.01.044.

## Variants in Solute Carrier *SLC26A9* Modify Prenatal Exocrine Pancreatic Damage in Cystic Fibrosis

Melissa R. Miller, PhD<sup>1</sup>, David Soave, MS<sup>1,2</sup>, Weili Li, MS<sup>1,2</sup>, Jiafen Gong, PhD<sup>1</sup>, Rhonda G. Pace, BS<sup>3</sup>, Pierre-Yves Boëlle, PhD<sup>4,5</sup>, Garry R. Cutting, MD<sup>6,7</sup>, Mitchell L. Drumm, PhD<sup>8</sup>, Michael R. Knowles, MD<sup>3</sup>, Lei Sun, PhD<sup>2,9</sup>, Johanna M. Rommens, PhD<sup>1,10</sup>, Frank Accurso, MD<sup>11,12</sup>, Peter R. Durie, MD FRCP(C)<sup>13,14</sup>, Harriet Corvol, MD, PhD<sup>4,15</sup>, Hara Levy, MD<sup>16,17</sup>, Marci K. Sontag, PhD<sup>12,18</sup>, and Lisa J. Strug, PhD<sup>1,2</sup>

<sup>1</sup>Program in Genetics and Genome Biology, the Hospital for Sick Children, Toronto, Ontario, Canada

<sup>2</sup>Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada

<sup>3</sup>Cystic Fibrosis-Pulmonary Research and Treatment Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

<sup>4</sup>Pierre et Marie Curie University-Paris 6, Paris, France

<sup>5</sup>Biostatistics Department, St Antoine Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP); Institut National de la Santé et la Recherche Médicale (INSERM), UMR-S 1136, Paris, France

<sup>6</sup>Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

<sup>7</sup>McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

<sup>8</sup>Departments of Pediatrics and Genetics, Case Western Reserve University, Cleveland, Ohio, USA

<sup>9</sup>Department of Statistical Sciences, University of Toronto, Toronto, Ontario, Canada

<sup>10</sup>Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada

<sup>11</sup>Department of Pediatrics, University of Colorado Denver School of Medicine, Aurora, Colorado, USA

<sup>12</sup>Department of Pediatrics, Children's Hospital of Colorado, Aurora, Colorado, USA

---

**Address correspondence and request for reprints to:** Lisa J Strug, PhD, Peter Gilgan Centre for Research & Learning, Room 12.9834, 686 Bay Street, Toronto, ON, M5G 0A4. Phone: (416) 813-7654 ext. 301762; Lisa.Strug@utoronto.ca.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The authors declare no conflicts of interest.

<sup>13</sup>Program in Physiology and Experimental Medicine, the Hospital for Sick Children, Toronto, Ontario, Canada

<sup>14</sup>Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada

<sup>15</sup>Pediatric Pulmonology Department, Trousseau Hospital, AP-HP, Inserm U938, Paris, France

<sup>16</sup>Department of Pediatrics, Section of Pulmonary and Sleep Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA

<sup>17</sup>Children's Research Institute, Children's Hospital of Wisconsin, Milwaukee, Wisconsin, USA

<sup>18</sup>Department of Epidemiology, Colorado School of Public Health University of Colorado Denver, Aurora, Colorado, USA

## Abstract

**Objectives**—To test the hypothesis that multiple constituents of the apical plasma membrane residing alongside the causal CF Transmembrane Conductance Regulator (CFTR) protein, including known cystic fibrosis (CF) modifiers *SLC26A9*, *SLC6A14*, and *SLC9A3*, would be associated with prenatal exocrine pancreatic damage as measured by newborn screened (NBS) IRT levels.

**Study design**—NBS IRT measures and genome-wide genotype data were available on 111 subjects from Colorado, 37 subjects from Wisconsin, and 80 subjects from France. Multiple linear regression was used to determine whether any of eight SNPs in *SLC26A9*, *SLC6A14* and *SLC9A3* were associated with IRT and whether other constituents of the apical plasma membrane contributed to IRT.

**Results**—In the Colorado sample, three *SLC26A9* SNPs were associated with NBS IRT (min  $P = 1.16 \times 10^{-3}$ ; rs7512462), but no *SLC6A14* or *SLC9A3* SNPs were associated ( $P > 0.05$ ). The rs7512462 association replicated in the Wisconsin sample ( $P = 0.03$ ) but not in the French sample ( $P = 0.76$ ). Furthermore, rs7512462 was the top ranked apical membrane constituent in the combined Colorado and Wisconsin sample.

**Conclusions**—NBS IRT is a biomarker of prenatal exocrine pancreatic disease in patients with CF, and a SNP in *SLC26A9* accounts for significant IRT variability. This suggests *SLC26A9* as a potential therapeutic target to ameliorate exocrine pancreatic disease.

## Keywords

immunoreactive trypsinogen (trypsinogen); exocrine pancreas; Modifier genes; newborn screening (neonatal screening or Newborn infant screening)

---

Cystic fibrosis (CF), a life-shortening, autosomal recessive disorder caused by mutations in the CF Transmembrane Conductance Regulator (*CFTR*) gene<sup>1</sup> affects multiple organs, including the pancreas. The CF pancreas is characterized by reduced luminal fluid secretion and concentrated acinar proteins that accumulate in the small ducts<sup>2, 3</sup>. Pancreatic ducts and acini show signs of obstruction from proteinaceous secretions *in utero*<sup>4</sup>, and damage continues in early life<sup>5</sup>. Postnatally, exocrine pancreatic tissue is replaced with fibrotic tissue and fat<sup>6, 7</sup>.

*CFTR* genotype is correlated with pancreatic disease severity, with pancreatic insufficiency primarily occurring in individuals with two severe *CFTR* genotypes<sup>8</sup>. However individuals with the same *CFTR* genotype have variable pancreatic disease at birth<sup>9</sup>, suggesting a role for additional genetic contributors. Serum levels of the pancreatic enzyme precursor, trypsinogen, measured by an immunoreactive trypsinogen (IRT) assay, are often elevated near birth in infants<sup>10</sup> with two CF-causing *CFTR* mutations<sup>11</sup>. Elevated IRT levels at birth are the primary biomarker of CF in newborn screening programs.

In individuals with *CFTR* genotypes associated with pancreatic insufficiency, the persistent IRT elevation in infancy is often followed by a progressive decline, with 95% of these individuals with CF having lower IRT levels than a non-CF population by age seven<sup>12</sup>. This is likely due to progression of pancreatic damage, reduced acinar mass, and reduced capacity to produce digestive enzymes such as trypsin. Thus, extrapolating backwards in an IRT-elevated CF population, lower IRT near birth is thought to reflect more severe pancreatic damage<sup>13</sup>. This is supported by the findings that lower IRT levels at birth is associated with the CF intestinal obstruction<sup>14</sup> meconium ileus<sup>15</sup>, and increased risk of CF-related diabetes<sup>13</sup>. However, explicitly evaluating this hypothesis *in vivo* would require human studies of CF pancreatic tissue.

Decline in IRT levels can be used to monitor acinar destruction postnatally and to predict the development of pancreatic insufficiency<sup>12, 16</sup>. Thus, IRT levels may represent a biomarker of exocrine pancreatic damage in CF. Measures of IRT in early infancy are heritable<sup>15</sup>, suggesting that NBS IRT may provide a tool to identify the genetic architecture of prenatal exocrine pancreatic damage in CF.

With loss of *CFTR* function, variation in multiple constituents of the apical plasma membrane contribute to the risk of meconium ileus, including 8 SNPs in three solute carriers, *SLC26A9*, *SLC6A14*, and *SLC9A3*<sup>17</sup>. In this study, we asked whether the meconium ileus risk-alleles in *SLC26A9*, *SLC6A14*, and *SLC9A3* were associated with early exocrine pancreatic damage as measured by NBS IRT and whether multiple apical plasma membrane constituents contribute to prenatal exocrine pancreatic damage.

## METHODS

All subjects were part of the Colorado, Wisconsin, or French sites of the International Cystic Fibrosis Gene Modifier Consortium, which collected DNA and clinical data from CF patients. All protocols were approved by institutional review boards. All participants provided written informed consent.

Individuals included for analysis were of European descent, had two severe *CFTR* mutations known to confer pancreatic insufficiency, and had an NBS IRT measurement. NBS IRT values were measured by Children's Hospital Denver (1982–1987) or the Colorado Department of Public Health and Environment (1987-current)<sup>11</sup>, the Wisconsin State Laboratory of Hygiene<sup>18</sup>, or regional screening laboratories in France<sup>19</sup>. All subjects at each site who had an NBS IRT were eligible to participate in the study.

## Quality Control (QC) and DNA Collection

Standard QC measures were performed as previously described<sup>17, 20</sup>. We did not identify any cryptic relatedness, sex incongruity, or non-European ancestry as determined by principal component analysis using Eigenstrat<sup>21</sup>. There were six sibling pairs genotyped in the Colorado sample, five in the Wisconsin sample, and no siblings in the French sample. All pairwise relationships were confirmed using identity by descent estimation in PLINK<sup>22</sup>, and one sibling from each pair was removed at random. The final analysis included 111 individuals from Colorado, and two replication samples of 37 and 80 individuals from Wisconsin and France, respectively. Commercially available IRT kits use different antibodies<sup>23</sup>, and Lafont et al note that these antibodies can have different specificity for trypsinogen or bind to different forms of trypsinogen present in serum<sup>24</sup>. Because of this, IRT measurements across sites may not be comparable. Hence, each of the three samples was analyzed separately. Colorado was the largest sample, and was treated as the discovery sample, with Wisconsin and France each used as a replication sample.

DNA was extracted from whole blood or transformed lymphocytes and quantified with fluorimetry. DNA of the French sample was genotyped using two genotyping platforms with different subsets of genetic markers, the Illumina CNV 370-Duo BeadChip or the Illumina 6620W-Quad BeadChip (660W). DNA of the Colorado and Wisconsin samples was genotyped simultaneously using the 660W. Individuals from Colorado or Wisconsin with missing genotype rate >2% (n = 22) were re-genotyped on the Illumina Omni5-Quad BeadChip (Omni5). There were 431,504 SNPs on the 660W and Omni5 that overlapped and passed QC.

Genotype imputation uses a reference set of population haplotypes to infer un-typed genotypes in a sample of interest. We used MaCH and Minimac<sup>25</sup> to impute the 22 individuals genotyped on the Omni5 at 79,159 SNPs unique to the 660W, and all French samples to the SNPs on the 660W (Figure 1; available at [www.jpeds.com](http://www.jpeds.com)). *SLC9A3* SNP rs17563161 was not present on either genotyping platform, and genotype calls for this SNP were imputed in the full sample. Imputed SNPs were required to have  $R^2 > 0.3$  and minor allele frequency  $\geq 5.0\%$ .

## NBS IRT Measurement and Assay

NBS for CF has been in place in Colorado since 1982<sup>11</sup>. In Wisconsin NBS for CF was available as a clinical trial from 1985 to 1994<sup>26</sup>, and available to all infants after 1994<sup>18</sup>. Nationwide NBS has been in place in France since 2002<sup>19</sup>, but previously existed in Normandy (1980)<sup>27</sup> and Brittany (1989)<sup>28</sup>. In Colorado and Wisconsin, IRT is measured by a single state laboratory; in France, it is measured at one of 22 regional laboratories<sup>19</sup>. In all three locations, newborn infants' blood is collected via a heel stick and placed on filter cards. IRT is extracted and measured from the dried blood spots.

The assays used to measure IRT have changed during the course of NBS at all three sites (Figure 2; available at [www.jpeds.com](http://www.jpeds.com)). Additional details of the assays and changes are published elsewhere<sup>11, 18, 19, 27, 29</sup>. The assay used in France until 2002 required all newborn infants with IRT  $\geq 900$  ng/ml undergo follow-up testing for CF. The IRT assay

changed in 2002, and the new assay had a positive CF-screening value of 60 ng/ml. In France, IRT values from the older assay are divided by 15 in order to make them comparable with values from the new assay.

### Statistical Analyses

All analyses were conducted using R<sup>30</sup>. Kruskal-Wallis tests were used to determine if IRT varied by assay in any of the sites, varied between sites, or varied with other covariates of interest. We used Spearman's correlation to test for a correlation between IRT and age of IRT measurement. Chi-square tests were used to determine if descriptive characteristics (i.e. sex, meconium ileus) varied significantly ( $P < 0.05$ ) by site.

In the Colorado sample, 8 SNPs were tested for associations with IRT individually using multiple linear regression. SNPs were coded additively as 0, 1, or 2, corresponding to the number of risk alleles defined by meconium ileus findings<sup>17</sup>. For chromosome X SNPs, males were coded as 0 or 2. Regression models for each SNP were adjusted for each of the following covariates separately: meconium ileus status, sex, *CFTR* genotype (delF508 homozygotes versus all others), IRT assay, and population structure using principal components. Inclusion of these covariates did not impact the results, and unadjusted results are presented, with adjusted results for the most significantly associated SNP presented in Tables V and VI (available at [www.jpeds.com](http://www.jpeds.com)). The effective number of independent tests across the 8 SNPs was estimated as 6 using the Genetics Type I Error Calculator software, which takes into account correlation between markers<sup>31</sup>. To adjust for multiple hypothesis testing, we required a significance level of  $\alpha = 0.0083$  ( $0.05/6$ ) to conclude statistical significance.

We assessed the evidence for replication of a SNP-IRT association identified in the Colorado sample, using the Wisconsin and French samples. We used the same statistical models and required the same risk allele to be associated, although all reported p-values are two-sided.

To determine if IRT has a complex genetic inheritance with multiple constituents of the apical plasma membrane contributing to pancreatic damage, we conducted a gene-set analysis of the apical constituents and a single-SNP analysis to assess significance at the individual markers annotated to the gene-set. As in the report by Sun et al<sup>17</sup>, a list of 157 genes that localize to the apical plasma membrane was identified. Because the majority of the study participants were genotyped on the 660W, we limited analysis to SNPs on this platform that passed QC with a minor allele frequency  $\geq 2.0\%$ . The distribution of IRT was similar between Colorado and Wisconsin ( $P = 0.57$ ); thus the two samples were combined ( $n = 148$ ) for the gene-set analysis with 3,614 SNPs. We repeated the gene-set analysis in the French sample (3,567 SNPs). We used permutation analysis to assess statistical significance of the Wald Chi-squared sum statistic across the 3,614 SNPs (Colorado and Wisconsin) or 3,567 SNPs (France) in the gene-set.

## RESULTS

The three samples are described in Table I. In France, all NBS blood samples were collected at three days of age, whereas in Colorado and Wisconsin the timing of the blood collection varied. The three sites are comparable in distribution of sex, percent with meconium ileus, and occurrence of delF508 mutations. IRT distribution does not differ between Colorado and Wisconsin, but is lower in France ( $P < 0.0001$ ) than either North American sample (Figure 3; available at [www.jpeds.com](http://www.jpeds.com)).

IRT does not vary by sex or *CFTR* genotype () in any of the three sites. IRT values are not correlated with age at IRT measurement (Colorado and Wisconsin; Figure 4 available at [www.jpeds.com](http://www.jpeds.com)). In Wisconsin, IRT levels were greater when measured with the radio-immunoassay than the time-resolved fluorometric assay ( $P = 0.008$ ; Figure 4). IRT is similar by assay in Colorado and France. IRT is lower in individuals with meconium ileus (Colorado:  $P = 0.002$ ; Wisconsin:  $P = 0.03$ ), though this does not reach statistical significance in the French sample ( $P = 0.09$ ; Figure 4).

In the Colorado sample, three SNPs in *SLC26A9* were associated with NBS IRT (min  $P = 1.16 \times 10^{-3}$  at rs7512462; Table II). No SNPs in *SLC9A3* ( $P = 0.50$ ) or *SLC6A14* (min  $P = 0.21$ ) showed evidence of association (Table II). Each additional copy of the rs7512462 meconium ileus risk allele<sup>17</sup> was associated with lower NBS IRT (i.e. worse pancreatic disease) of 49 ng/ml (95% Confidence Interval (CI): (-78, -20)); this SNP explained 9% of the variability in NBS IRT. The distribution of IRT by number of rs7512462 risk alleles is presented in Figure 4. Limiting the analysis to individuals homozygous for the *CFTR* delF508 mutation ( $n = 62$ ) resulted in similar findings ( $P = 6.65 \times 10^{-3}$ ;  $\beta = -50$  ng/ml). The three associated SNPs in *SLC26A9* are in reasonably high linkage disequilibrium (Figure 5).<sup>32</sup> After adjusting for the effect of rs7512462, the other SNPs were no longer associated ( $P = 0.45$  and  $0.19$  for rs4077468 and rs12047830, respectively) suggesting the three SNPs tag the same underlying genetic cause.

In the Wisconsin sample, rs7512462 was significantly associated with NBS IRT ( $P = 0.03$ ,  $\beta = -57$  ng/ml, 95% CI: -108, -6; Table III) and explained ~13% of the variability in IRT. Evidence for association was similar in the delF508 homozygous group ( $n = 27$ ;  $p = 0.023$ ;  $\beta = -66$  ng/ml). There was no evidence that rs7512462 contributed to variability in the French measure of NBS IRT ( $P = 0.76$ ,  $\beta = 3$  ng/ml, 95% CI: (-18, 24)), and this was similar when limiting to the delF508 homozygous group ( $n = 52$ ,  $p = 0.76$ ,  $\beta = 4$  ng/ml). When the two North American samples were combined, evidence for association between NBS IRT and rs7512462 was similar to the site specific samples ( $P = 6.77 \times 10^{-5}$ ;  $\beta = -51$  ng/ml, 95% CI: (-76, -26)); rs7512462 explained ~10% of the variance in IRT. Evidence for association was similar in the delF508 homozygous group ( $n = 89$ ,  $p = 6.65 \times 10^{-3}$ ,  $\beta = -55$  ng/ml). Covariate adjustment did not impact these results (Tables IV and V; Table IV available at [www.jpeds.com](http://www.jpeds.com)). Imputation of the *SLC26A9* region did not identify any additional SNPs that were more strongly associated with NBS IRT than rs7512462 (Figure 5).

We did not find significant evidence of a complex genetic architecture for exocrine pancreatic disease as measured by NBS IRT, with multiple constituents of the apical plasma



membrane contributing to early exocrine pancreatic damage ( $p = 0.26$ ; Figure 6 available at [www.jpeds.com](http://www.jpeds.com)). Further, when we examine the association evidence from the individuals SNPs in this group, rs7512462 in *SLC26A9* is the top ranked SNP (Table VI) with no other SNP reaching an experiment-wise ( $0.05/3614 = 1.38 \times 10^{-5}$ ) significance level.

Similarly, in the French sample, we did not find any evidence that multiple constituents contributed to early exocrine pancreatic damage ( $P = 0.46$ ; Figure 6), and there are no individual SNPs annotated to the 155 genes that reach experiment-wise significance (Table VII; available at [www.jpeds.com](http://www.jpeds.com)).

## DISCUSSION

We found a strong association between *SLC26A9* rs7512462 and prenatal exocrine pancreatic disease in a sample of individuals with CF from Colorado. This association replicated in a sample of individuals with CF from Wisconsin, but not in a sample from France. In both the Colorado and Wisconsin samples, the rs7512462 meconium ileus risk allele was associated with more severe pancreatic disease, as indicated by a lower newborn screened IRT value; provided similar effect size estimates; and accounted for a similar and substantial amount of the variability in NBS IRT. We did not find any SNPs in *SLC6A14* or *SLC9A3* that were associated with early exocrine pancreatic disease severity. This supports previous findings that *SLC6A14* and *SLC9A3* are associated with CF pulmonary phenotypes, but not pancreatic phenotypes<sup>33</sup>, and is consistent with known expression data. Based upon a study of human adult tissues<sup>34</sup>, *SLC9A3* is abundantly expressed in kidney and small intestine, and *SLC6A14* is abundantly expressed in human lung and salivary gland. Lohi et al report expression of *SLC26A9* in the human pancreas<sup>35</sup>. Pancreatic expression was not reported in a study of adult human tissues<sup>34</sup>, although the importance of *SLC26A9* function in the gastrointestinal tract of very young mice has been reported<sup>36</sup>. *SLC26A9* encodes an anion transporter that can mediate chloride-bicarbonate exchange and sodium-coupled transport<sup>37</sup>. It can physically interact with CFTR and be influenced by CFTR activity<sup>38, 39</sup>. In CF, with the loss of CFTR function at the apical plasma membrane, *SLC26A9* may augment ion transport and fluid flow, explaining its modifying effect. From a clinical perspective, individuals diagnosed with CF through newborn screening could be screened for rs7512462. Individuals who carry the risk allele may have worse pancreatic damage and could be monitored more closely for failure to thrive and the need to start enzyme treatments sooner.

We were unable to find evidence of a complex genetic model for CF exocrine pancreatic disease with multiple apical constituents contributing to NBS IRT, unlike for other CF comorbidities such as meconium ileus and lung disease<sup>17, 33</sup>. However, for other CF comorbidities, individual associated SNPs accounted for much less than 10% of trait variability, which is consistent with a complex inheritance model.

Multiple factors could explain the lack of association with rs7512462 in the French sample. It is possible that a different constituent of the apical plasma membrane contributes to exocrine pancreatic damage in the French sample, and we were underpowered to detect this. Another explanation is that the French sample differed fundamentally from the American



samples. IRT was assayed at one of 22 regional laboratories in France, whereas the Wisconsin and Colorado sites each have centralized measurements of IRT, introducing more heterogeneity in the French sample. Moreover, different commercial IRT kits use different antibodies<sup>23</sup>, which have different specificity for trypsinogen or bind to different forms of trypsinogen present in serum<sup>24</sup>. Further, there is no certified IRT reference material, so the IRT provided as a reference can vary in level in different kits<sup>40</sup>. Finally, the stability of IRT measured from blood spots may be affected by transport time from the hospital to the testing facility and the climate of the area<sup>41</sup>. All of these factors could affect the IRT levels measured in the French sample, leading to the observed difference in IRT distribution across the samples and the lack of rs7512462 association. We were unable to link the specific laboratory corresponding to individual IRT measurements in the French data to determine if the IRT values differed by site.

A limitation of this study is the relatively small sample size available, which precluded interrogation of the whole genome for markers associated with prenatal exocrine pancreatic damage. However, the observed difference in IRT distribution between the French and American samples provide a note of caution for future studies that may wish to use the NBS IRT values from multiple sites/laboratories in order to increase their sample sizes. Not all CF IRT-based newborn screening protocols result in equally interpretable biomarkers. A second limitation is that the study was restricted to individuals of European ancestry, and therefore our results only generalize to that population.

Despite changes to the assay, the ratio of signal to noise was strong enough that we were able to use the NBS IRT value from the Colorado and Wisconsin samples as a biomarker to reflect prenatal exocrine pancreatic disease severity in CF and identify a gene modifier, suggesting that NBS IRT has utility beyond a threshold for determining CF. Further investigation is required to disentangle which assays may be more or less useful for this purpose outside of those considered here.

Prenatal exocrine pancreatic damage in CF is influenced by the solute carrier *SLC26A9* with one SNP in this gene accounting for a substantial percentage of the variability in NBS IRT. The robust finding that *SLC26A9* is a CF gene modifier and a marker of CF pancreatic disease severity suggests a potential therapeutic target to slow the progression of exocrine pancreatic damage in CF.

## Acknowledgments

The authors would like to thank the patients and families who participated in the study. We would also like to thank Jaclyn Stonebraker for assistance in sample processing, data handling, and useful discussion; Jacques Brouard, Michel Roussey, Valérie David, Christophe Marguet, and Pauline Touche for patient recruitment and the data collection of the French sample; Melissa Reske and Rachel Bersie for patient recruitment and data collection of the Wisconsin sample; and Meg Anthony for patient recruitment and study design of the Colorado sample.

Funding support information is available at [www.jpeds.com](http://www.jpeds.com) (Appendix).

Funded by the Canadian Institutes of Health Research (MOP-258916 [to L.S.]), Cystic Fibrosis Canada (2626 [to L.S.]), the National Institutes of Health/National Heart Lung and Blood Institute (R01 HL068890-10 [to M.K.] and DP20D007031 [to H.L.]), National Institute of Diabetes and Digestive and Kidney Diseases (1R01 DK61886-01 [to F.A.]), the Children's Hospital of Wisconsin Research Institute (to H.L.), and the United States Cystic Fibrosis Foundation (Sontag07AO and Miller13A0). Funds for genome-wide genotyping of North American participants

were generously provided by the United States Cystic Fibrosis Foundation. H.C. and P.-Y. B. are supported by the Institut National de la Santé et de la Recherche Médicale, Assistance Publique-Hôpitaux de Paris, Université Pierre et Marie Curie Paris, Agence Nationale de la Recherche (R09186DS), DGS, Association Vaincre La Mucoviscidose, Chancellerie des Universités (Legs Poix), Association Agir Informer Contre la Mucoviscidose, and GIS-Institut des Maladies Rares. M.M., W.L., and D.S. are fellows of the CIHR Strategic Training for Advanced Genetic Epidemiology and Statistical Genetics.

## ABBREVIATIONS


<b>CF</b>	Cystic Fibrosis
<b>CFTR</b>	Cystic Fibrosis Transmembrane Conductance Regulator
<b>CI</b>	Confidence Interval
<b>IRT</b>	Immunoreactive Trypsinogen
<b>NBS</b>	newborn screened/newborn screening
<b>Omni5</b>	Illumina Omni5-Quad BeadChip
<b>QC</b>	quality control
<b>660W</b>	Illumina 660W-Quad BeadChip

## References


1. Kerem B, Rommens J, Buchanan J, Markiewicz D, Cox T, Chakravarti A, et al. Identification of the cystic fibrosis gene: genetic analysis. *Science*. 1989; 245:1073–80. [PubMed: 2570460]
2. Kopelman H, Corey M, Gaskin K, Durie P, Weizman Z, Forstner G. Impaired chloride secretion, as well as bicarbonate secretion, underlies the fluid secretory defect in the cystic fibrosis pancreas. *Gastroenterology*. 1988; 95:349–55. [PubMed: 3391365]
3. Kopelman H, Durie P, Gaskin K, Weizman Z, Forstner G. Pancreatic fluid secretion and protein hyperconcentration in cystic fibrosis. *N Engl J Med*. 1985; 312:329–34. [PubMed: 3969086]
4. Boue A, Muller F, Nezelof C, Oury JF, Duchatel F, Dumez Y, et al. Prenatal diagnosis in 200 pregnancies with a 1-in-4 risk of cystic fibrosis. *Hum Genet*. 1986; 74:288–97. [PubMed: 3536726]
5. Imrie JR, Fagan DG, Sturgess JM. Quantitative evaluation of the development of the exocrine pancreas in cystic fibrosis and control infants. *Am J Pathol*. 1979; 95:697–708. [PubMed: 453330]
6. Oppenheimer EH, Esterly JR. Pathology of cystic fibrosis review of the literature and comparison with 146 autopsied cases. *Perspect Pediatr Pathol*. 1975; 2:241–78. [PubMed: 1168897]
7. Iannucci A, Mukai K, Johnson D, Burke B. Endocrine pancreas in cystic fibrosis: an immunohistochemical study. *Hum Pathol*. 1984; 15:278–84. [PubMed: 6365738]
8. Ahmed N, Corey M, Forstner G, Zielenski J, Tsui L-C, Ellis L, et al. Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas. *Gut*. 2003; 52:1159–64. [PubMed: 12865275]
9. Bronstein MN, Sokol RJ, Abman SH, Chatfield BA, Hammond KB, Hambidge KM, et al. Pancreatic insufficiency, growth, and nutrition in infants identified by newborn screening as having cystic fibrosis. *J Pediatr*. 1992; 120:533–40. [PubMed: 1552390]
10. Crossley JR, Elliot RB, Smith PA. Dried-blood spot screening for cystic fibrosis in the newborn. *The Lancet*. 1979; 313:472–4.
11. Sontag MK, Hammond KB, Zielenski J, Wagener JS, Accurso FJ. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes. *J Pediatr*. 2005; 147:S83–S8. [PubMed: 16202790]
12. Durie PR, Forstner GG, Gaskin KJ, Moore DJ, Cleghorn GJ, Wong SS, et al. Age-related alterations of immunoreactive pancreatic cationic trypsinogen in sera from cystic fibrosis patients with and without pancreatic insufficiency. *Pediatr Res*. 1986; 20:209–13. [PubMed: 3703609]

13. Soave D, Miller M, Keenan K, Li W, Gong J, Ip W, et al. Evidence for a causal relationship between early exocrine pancreatic disease and cystic fibrosis-related diabetes: A Mendelian randomization study. *Diabetes*. 2014; 63:2114–9. [PubMed: 24550193]
14. Welsh, MJ.; Ramsey, BW.; Accurso, FJ.; Cutting, GR. Cystic fibrosis. In: Scriver, CR.; Sly, WS.; Childs, B., et al., editors. *The metabolic and molecular bases of inherited disease*. Vol. III. New York: McGraw-Hill, Inc; 2001. p. 5121-5188.
15. Sontag MK, Corey M, Hokanson JE, Marshall JA, Sommer SS, Zerbe GO, et al. Genetic and physiologic correlates of longitudinal immunoreactive trypsinogen decline in infants with cystic fibrosis identified through newborn screening. *J Pediatr*. 2006; 149:650–7.e2. [PubMed: 17095337]
16. Couper RTL, Corey M, Moore DJ, Fisher LJ, Forstner GG, Durie PR. Decline of exocrine pancreatic function in cystic fibrosis patients with pancreatic sufficiency. *Pediatr Res*. 1992; 32:179–82. [PubMed: 1508606]
17. Sun L, Rommens JM, Corvol H, Li W, Li X, Chiang TA, et al. Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. *Nat Genet*. 2012; 44:562–9. [PubMed: 22466613]
18. Rock MJ, Hoffman G, Laessig RH, Kopish GJ, Litsheim TJ, Farrell PM. Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing. *J Pediatr*. 2005; 147:S73–S7. [PubMed: 16202788]
19. Munck A, Dhondt J-L, Sahler C, Roussey M. Implementation of the French nationwide cystic fibrosis newborn screening program. *J Pediatr*. 2008; 153:228–33.e1. [PubMed: 18534227]
20. Wright FA, Strug LJ, Doshi VK, Commander CW, Blackman SM, Sun L, et al. Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. *Nat Genet*. 2011; 43:539–46. [PubMed: 21602797]
21. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet*. 2006; 38:904–9. [PubMed: 16862161]
22. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira M, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet*. 2007; 81:559–75. [PubMed: 17701901]
23. Lindau-Shepard BA, Pass KA. Newborn screening for cystic fibrosis by use of a multiplex immunoassay. *Clin Chem*. 2010; 56:445–50. [PubMed: 20040620]
24. Lafont P, Guy-Crotte O, Paulin C, Galvain D, Mertani S, Figarella C, et al. A specific immunoradiometric assay of cationic trypsin(ogen) that does not recognize trypsin-alpha-1-proteinase inhibitor complex. *Clin Chim Acta*. 1995; 235:197–206. [PubMed: 7554274]
25. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. *Genet Epidemiol*. 2010; 34:816–34. [PubMed: 21058334]
26. Fost N, Farrell PM. A prospective randomized trial of early diagnosis and treatment of cystic fibrosis: a unique ethical dilemma. *Clin Res*. 1989; 37:495–500. [PubMed: 2673641]
27. Brouard J, Lecoq I, Viel JF, Guillot M, Laurans M, Laroche D, et al. Evaluation of diagnosis and follow-up in screened children with cystic fibrosis in Normandy. *Arch Pediatr*. 2001; 8(Suppl 3): 603–9. [PubMed: 11683083]
28. Scotet V, de Braekeleer M, Roussey M, Rault G, Parent P, Dagonne M, et al. Neonatal screening for cystic fibrosis in Brittany, France: assessment of 10 years' experience and impact on prenatal diagnosis. *The Lancet*. 2000; 356:789–94.
29. Farrell PM, Kosorok MR, Laxova A, Shen G, Kosciak RE, Bruns WT, et al. Nutritional benefits of neonatal Screening for cystic fibrosis. *N Engl J Med*. 1997; 337:963–9. [PubMed: 9395429]
30. R Development Core Team. *R: A language and environment for statistical computing*. Vienna, Austria: R Foundation for Statistical Computing; 2011.
31. Li M-X, Yeung JY, Cherny S, Sham P. Evaluating the effective numbers of independent tests and significant p-value thresholds in commercial genotyping arrays and public imputation reference datasets. *Hum Genet*. 2012; 131:747–56. [PubMed: 22143225]


32. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, et al. LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics*. 2010; 26:2336–7. [PubMed: 20634204]
33. Li W, Soave D, Miller M, Keenan K, Lin F, Gong J, et al. Unraveling the complex genetic model for cystic fibrosis: pleiotropic effects of modifier genes on early cystic fibrosis-related morbidities. *Hum Genet*. 2013:1–11. [PubMed: 23001594]
34. Fagerberg L, Hallström BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. *Mol Cell Proteomics*. 2014; 13:397–406. [PubMed: 24309898]
35. Lohi H, Kujala M, Makela S, Lehtonen E, Kestila M, Saarialho-Kere U, et al. Functional characterization of three novel tissue-specific anion exchangers SLC26A7, -A8, and -A9. *J Biol Chem*. 2002; 277:14246–54. [PubMed: 11834742]
36. Liu X, Li T, Riederer B, Lenzen H, Ludolph L, Yeruva S, et al. Loss of Slc26a9 anion transporter alters intestinal electrolyte and HCO<sub>3</sub><sup>-</sup> transport and reduces survival in CFTR-deficient mice. *Pflugers Arch*. 2014:1–15.
37. Chang MH, Plata C, Zandi-Nejad K, Sindic A, Sussman CR, Mercado A, et al. Slc26a9–anion exchanger, channel and Na<sup>+</sup> transporter. *J Membr Biol*. 2009; 228:125–40. [PubMed: 19365592]
38. Bertrand CA, Zhang R, Pilewski JM, Frizzell RA. SLC26A9 is a constitutively active, CFTR-regulated anion conductance in human bronchial epithelia. *J Gen Physiol*. 2009; 133:421–38. [PubMed: 19289574]
39. Avella M, Loriol C, Boulukos K, Borgese F, Ehrenfeld J. SLC26A9 stimulates CFTR expression and function in human bronchial cell lines. *J Cell Physiol*. 2011; 226:212–23. [PubMed: 20658517]
40. Li L, Zhou Y, Bell CJ, Earley MC, Hannon WH, Mei JV. Development and characterization of dried blood spot materials for the measurement of immunoreactive trypsinogen. *J Med Screen*. 2006; 13:79–84. [PubMed: 16792830]
41. Therrell BL Jr, Hannon WH, Hoffman G, Ojodu J, Farrell PM. Immunoreactive trypsinogen (IRT) as a biomarker for cystic fibrosis: Challenges in newborn dried blood spot screening. *Mol Genet Metab*. 2012; 106:1–6. [PubMed: 22425451]



**Figure 1.** Methodology for combining genotypes for individuals from Colorado and Wisconsin genotyped on the Illumina 660W-Quad BeadChip and re-genotyped on the Illumina Omni5-Quad BeadChip. Standard quality control was performed on all genotypes.




**Figure 2.** Changes to the IRT assay over time in each site. The x-axis represents year of measurement, and each box indicated the type of assay used, including the (1) assay name, (2) manufacturer, (3) type of assay, and (4) percent of subjects in each site that used that assay.




**Figure 3.** Distribution of NBS IRT in Colorado, Wisconsin and French samples. Box represents 25<sup>th</sup>, 50<sup>th</sup> (median), and 75<sup>th</sup> percentile. Whiskers represent 5<sup>th</sup> and 95<sup>th</sup> percentiles, and open circles represent values above the 95<sup>th</sup> percentile.






**Figure 4.** Distribution of NBS IRT is compared, within each site, by the following variables of interest: *Sex* (row 1): males versus female. *CFTR mutation* (row 2): Subjects are classified as delF508 homozygotes (DFDF) versus all others. *Age at IRT* (row 3): Correlation of age at IRT with IRT value (Colorado and Wisconsin only; In France, IRT is measured at 3 days of age). *Assay* (row 4): Categorized by the technology used to measure IRT, either radio-immunoassay (RIA), or a time-resolved fluorometric assay (FIA). *Meconium ileus status* (row 5): subjects with meconium ileus (MI) versus those without MI. Total n may be

reduced as some subjects are missing MI status. *Number of rs7512462 risk alleles* (row 6): 0, 1, or 2 risk alleles. P-values for sex, assay, MI status and *CFTR* determined using Kruskal-Wallis tests. P-value for rs7512462 determined using linear regression. Age at IRT correlation determined using Spearman's correlation. Box represents 25<sup>th</sup>, 50<sup>th</sup> (median), and 75<sup>th</sup> percentile. Whiskers represent 5<sup>th</sup> and 95<sup>th</sup> percentiles, and open circles represent values above the 95<sup>th</sup> percentile.



**Figure 5.** Regional plot for *SLC26A9* in the combined Colorado and Wisconsin sample. LocusZoom viewer<sup>32</sup> was used to show association evidence around *SLC26A9* based on human genome build 19. Symbol coloring represents LD  $r^2$  values of the 1000 genomes European sample with the most significant SNP.



**Figure 6.**

There is no evidence of association between NBS IRT and the apical plasma membrane constituents in the Colorado and Wisconsin samples ( $n = 148$ ) or in the French samples ( $n = 80$ ). As in Sun et al.<sup>17</sup>, a list of 157 genes that localize to the apical plasma membrane was identified. We included 3,614 SNPs (Colorado and Wisconsin) or 3,567 SNPs (French) from the Illumina 660W-Quad BeadChip with minor allele frequency  $>2\%$  that were annotated to  $\pm 10$  kb of the boundaries of the 155 genes. Two genes were not tagged by any GWAS SNPs. (A) Quantile-quantile plot in the combined Colorado and Wisconsin samples. The observed association statistics (black dotted line) and the statistics calculated from 10,000 IRT permuted replicates (gray) are shown. (B) Statistical significance of the apical plasma membrane hypothesis in the combined Colorado and Wisconsin samples. P-value (0.26) was established via a statistic that summed over the association evidence (Wald chi-squared statistic) of all the 3,614 SNPs with the observed sum statistic shown as a vertical line (black) and 10,000 permutation-based sum statistics shown as a histogram. (C) Quantile-quantile plot in the French replication sample. (D) Statistical significance of the apical membrane hypothesis in the French replication sample ( $P = 0.46$ ).

**Table 1**

Characteristics of 228 CF individuals with a NBS IRT value by site.

	Site		
	Colorado (n = 111)	Wisconsin (n = 37)	France (n = 80)
IRT, ng/ml, mean (SD)	255 (116)	236 (101)	151 (68)
Age at IRT measurement, days, median (IQR)	2 (1–3)	3 (2–4)	3 (NA) <sup>a</sup>
Year of birth, range	1983–2008	1986–2006	1981–2006
Male, n (%)	46 (41)	21 (57)	41 (51)
Meconium ileus positive, n (%)	23 (22) <sup>b</sup>	9 (24)	14 (18) <sup>c</sup>
Number p.Phe508del mutations, n (%) <sup>d</sup>			
0	4 (4)	1 (3)	3 (4)
1	45 (41)	9 (24)	24 (30)
2	62 (56)	27 (73)	53 (66)

SD, standard deviation; IQR, inter-quartile range

<sup>a</sup>: All blood samples are drawn at 3 days of age in this sample<sup>b</sup>: Based on a sample size of 103; 8 subjects missing meconium ileus status.<sup>c</sup>: Based on a sample size of 76; 4 subjects missing meconium ileus status.<sup>d</sup>: Cells may not sum to 100% due to rounding.

Table 2

Association of eight candidate SNPs with NBS IRT values in 111 subjects from Colorado.

SNP	Chromosome	Position <sup>a</sup>	Gene	Risk Allele <sup>b</sup>	Risk Allele Frequency	P value	$\beta$ (95% CI)	R <sup>2</sup>
rs7512462	1	204166218	SLC26A9	T	0.57	$1.16 \times 10^{-3}$	-49 (-78, -20)	0.09
rs4077468	1	204181380	SLC26A9	T	0.55	$7.20 \times 10^{-3}$	-38 (-66, -11)	0.06
rs12047830	1	204183322	SLC26A9	C	0.50	$1.92 \times 10^{-3}$	-47 (-77, -18)	0.08
rs7419153	1	204183932	SLC26A9	T	0.37	0.02	-34 (-63, -5)	0.05
rs17563161	5	550624	SLC9A3	T	0.28	0.50	13 (-24, 49)	0.00
rs12839137	X	115479578	SLC6A14	C	0.84	0.87	-3 (-39, 32)	0.00
rs5905283	X	115479909	SLC6A14	C	0.63	0.21	-16 (-42, 10)	0.01
rs3788766	X	115480867	SLC6A14	T	0.73	0.41	-12 (-40, 17)	0.01

CI, Confidence Interval

<sup>a</sup> : Based on Genome Reference Consortium Human Reference 37/Human Genome 19.

<sup>b</sup> : Meconium ileus risk allele from Sun et al<sup>16</sup>.

**Table 3**

Association of *SLC26A9* rs7512462 with NBS IRT values by site.

Site	N	rs7512462 Risk Allele Frequency	P value	$\beta$ (95% CI)	R <sup>2</sup>
Colorado	111	0.57	$1.16 \times 10^{-3}$	-49 (-78, -20)	0.09
Wisconsin	37	0.69	0.03	-57 (-108, -6)	0.13
France	80	0.62	0.76	3 (-18, 24)	0.00
Colorado + Wisconsin	148	0.60	$6.77 \times 10^{-5}$	-51 (-76, -26)	0.10

CI, Confidence Interval



**Table 4**

Covariate adjustment for association of *SLC26A9* SNP rs7512462 with NBS IRT in the Colorado and Wisconsin combined samples (n = 148).

Covariate in Model	$P_{\text{SNP}}$	$\beta_{\text{SNP}}$ (95% CI)	$P_{\text{covariate}}$	$R^2$ model
None (rs7512462 only)	$6.77 \times 10^{-5}$	-51 (-76, -26)	N/A	0.10
Sex	$7.30 \times 10^{-5}$	-51 (-76, -26)	0.72	0.10
CFTR <sup>a</sup>	$2.02 \times 10^{-5}$	-56 (-80, -31)	0.06	0.13
Age at IRT measurement (days)	$1.56 \times 10^{-4}$	-51 (-77, -25)	0.95	0.10
IRT assay	$4.85 \times 10^{-5}$	-52 (-77, -28)	0.16	0.12
Meconium ileus <sup>b</sup>	$1.37 \times 10^{-4}$	-48 (-72, -24)	$1.90 \times 10^{-4}$	0.19
Principal components <sup>c</sup>	$2.32 \times 10^{-5}$	-56 (-81, -31)	0.15	0.13
Site	$9.87 \times 10^{-5}$	-51 (-77, -25)	0.74	0.10

<sup>a</sup>: Subjects are classified as delF508 homozygotes versus all other mutations.

<sup>b</sup>: Based on a total sample of 140; 8 subjects are missing Meconium ileus status.

<sup>c</sup>: Adjusted for population structure, based on the first four principal components.

**Table 5**

Covariate adjustment for association of rs7512462 with NBS IRT in the French sample (n = 80).

Covariate in Model	p <sub>SNP</sub>	β <sub>SNP</sub> (95% CI)	p <sub>covariate</sub>	R <sup>2</sup> model
None (rs7512462 only)	0.76	3 (-18, 24)	NA	0.00
Sex	0.78	3 (-18, 24)	0.35	0.01
CFTR <sup>a</sup>	0.72	4 (-18, 25)	0.58	0.01
IRT assay	0.67	5 (-17, 26)	0.38	0.02
Meconium ileus <sup>b</sup>	0.83	3 (-20, 25)	0.33	0.01
Principal components <sup>c</sup>	0.83	2 (-19, 24)	0.64	0.06

<sup>a</sup>: Subjects are classified as delF508 homozygotes versus all other mutations.

<sup>b</sup>: Based on a total sample of 140; 8 subjects are missing Meconium ileus status.

<sup>c</sup>: Adjusted for population structure, based on the first four principal components.

**Table 6**

Top ranked apical plasma membrane constituents in the combined Colorado and Wisconsin samples (n = 148).

SNP	Chromosome	Position <sup>a</sup>	P value	Gene
rs7512462	1	205899595	$6.77 \times 10^{-5}$	<i>SLC26A9</i>
rs242050	1	4789179	$3.72 \times 10^{-4}$	<i>AJAP1</i>
rs12047830	1	205916699	$7.61 \times 10^{-4}$	<i>SLC26A9</i>
rs7415921	1	205910883	$8.80 \times 10^{-4}$	<i>SLC26A9</i>
rs7232775	18	43202404	$1.42 \times 10^{-3}$	<i>SLC14A2</i>
rs9675236	17	58226800	$1.70 \times 10^{-3}$	<i>CA4</i>
rs4077468	1	205914757	$2.24 \times 10^{-3}$	<i>SLC26A9</i>
rs4077469	1	205914885	$2.24 \times 10^{-3}$	<i>SLC26A9</i>
rs2627907	17	58218881	$2.63 \times 10^{-3}$	<i>CA4</i>
rs1321507	6	51826281	$3.41 \times 10^{-3}$	<i>PKHD1</i>

<sup>a</sup>: Based on Genome Reference Consortium Human Reference 37/Human Genome 19.

**Table 7**

Top ranked apical plasma membrane constituents in the French sample (n = 80).

SNP	Chromosome	Position <sup>a</sup>	P value	Gene
rs35806	10	79165830	$6.58 \times 10^{-4}$	<i>KCNMA1</i>
rs776385	8	31736625	$1.88 \times 10^{-3}$	<i>NRG1</i>
rs4458837	8	32304383	$1.90 \times 10^{-3}$	<i>NRG1</i>
rs1425802	11	35158401	$1.96 \times 10^{-3}$	<i>CD44</i>
rs673195	10	79164857	$2.61 \times 10^{-3}$	<i>KCNMA1</i>
rs11802794	1	197372250	$2.95 \times 10^{-3}$	<i>CRB1</i>
rs353625	11	35168546	$3.45 \times 10^{-3}$	<i>CD44</i>
rs6718187	2	44082362	$4.69 \times 10^{-3}$	<i>ABCG8</i>
rs4148179	2	44056856	$4.72 \times 10^{-3}$	<i>ABCG5</i>
rs4148178	2	44057030	$4.72 \times 10^{-3}$	<i>ABCG5</i>

<sup>a</sup>: Based on Genome Reference Consortium Human Reference 37/Human Genome 19.